Tectonic Therapeutic, Inc. (TECX)
$21.31-4.65%Close
SELLCRISIS · day 31
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $402M
- Beta
- 0.22
- P/E (TTM)
- -4.66
- Short % float
- 23.44%
- Days to cover
- 8.1
- SI change
- +0.2%
- 1W
- -4.91%
- 1M
- -28.27%
- vs SPY 1W
- -4.77%
- vs SPY 1M
- -30.78%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 14
- VALUE
- 8
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-21.2%
REV YoY-
ROE-35.3%
EPS YoY-
ROA-36.2%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-4.66
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.81
P/FCF-
EV/EBITDA-2.14
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.97
ALTMAN Z-
CURR RATIO22.29
ND/EBITDA-
BETA0.22
Company news
FAQ
- What is LOPJLB’s current signal on TECX?
- LOPJLB’s latest quantitative signal on Tectonic Therapeutic, Inc. (TECX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is TECX in?
- Tectonic Therapeutic, Inc. (TECX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Tectonic Therapeutic, Inc. (TECX) do?
- Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medici…